Cardinal Health Q3 Awaited Amid Growth Spurt and Strategic Shifts

DUBLIN, Ohio – March 24, 2026 – As Cardinal Health prepares to release its third-quarter financial results for fiscal year 2026 on April 30, all eyes are on the healthcare giant to see if it can sustain the powerful momentum that has defined its recent performance. The routine announcement belies the high stakes for a company that is rapidly transforming from a traditional pharmaceutical distributor into a diversified, specialty-focused growth platform.

Investors and industry analysts will be scrutinizing the report for confirmation that the company's aggressive strategy, marked by significant acquisitions and a pivot towards high-growth sectors, is continuing to fuel the impressive earnings beats and guidance raises seen in the first half of the fiscal year. The pre-market release will be followed by a webcast at 8:30 a.m. Eastern, where executives are expected to provide color on the company’s performance and its outlook amid a dynamic healthcare landscape.

Riding a Wave of Financial Momentum

Expectations for the third quarter are exceptionally high, built on a foundation of stellar results from the previous two quarters. In its second-quarter report, Cardinal Health posted a remarkable 36% year-over-year increase in non-GAAP earnings per share (EPS) to $2.63, crushing analyst estimates. This followed a similar performance in the first quarter, where non-GAAP EPS also grew by 36%.

This robust performance prompted management to raise its full-year fiscal 2026 non-GAAP EPS guidance twice, now sitting at a range of $10.15 to $10.35. This figure has outpaced consensus expectations and has been a primary driver of the stock's strong performance, which saw a total shareholder return of 58% over the past year. Analysts are now projecting an EPS of around $2.79 for the upcoming third-quarter report, setting a high bar for the company to clear.

The engine behind this growth has been the Pharmaceutical and Specialty Solutions segment. In the second quarter, this segment's revenue surged 19% to $60.7 billion, with its profit climbing 29%. This performance reflects the success of Cardinal Health's strategic focus on higher-margin specialty pharmaceuticals and its growing network of Management Services Organizations (MSOs), which support independent physician practices.

Beyond Distribution: A Strategy of Diversification

While its core distribution business remains massive, Cardinal Health's future is increasingly being shaped by its strategic diversification. The company has made several multi-billion dollar acquisitions to deepen its presence in specialty care and home health, areas experiencing significant tailwinds from an aging population and the rise of personalized medicine.

In November 2025, the company completed its $1.9 billion acquisition of Solaris Health, a leading urology MSO. This move dramatically scaled Cardinal Health's Urology Alliance and strengthened its position in the specialty MSO market. This followed the planned acquisition of GI Alliance, a major gastroenterology MSO, for approximately $2.8 billion, further cementing its strategy to build a multi-specialty platform.

These moves are already bearing fruit. The company's "Other" segment, which includes its at-Home Solutions and Nuclear and Precision Health Solutions businesses, has been a standout performer. This segment's growth was significantly bolstered by the April 2025 acquisition of Advanced Diabetes Supply (ADS). In the second quarter of fiscal 2026, the segment’s revenue grew 34% to $1.7 billion, while its profit jumped an impressive 52% to $179 million. This highlights the success of tapping into the burgeoning home medical equipment market, which is projected to exceed $60 billion by 2030.

Navigating a Complex Healthcare Supply Chain

Cardinal Health's financial success is occurring within a complex and challenging industry environment. The entire healthcare sector is grappling with persistent financial pressures, workforce constraints, and the ever-present threat of cyberattacks. However, the distribution subsector, in particular, is experiencing strong top-line growth. Key competitor McKesson Corporation also reported a strong quarter, with revenues increasing 11% and adjusted EPS growing 16%, signaling healthy demand across the industry.

Cardinal Health's ability to manage this environment will be a key focus of the Q3 report. The company is investing heavily in technology and automation across its distribution network to enhance efficiency and support the growing demand for home-delivered medical supplies. With three of eleven planned next-generation distribution centers already complete, investors will look for updates on this long-term operational upgrade.

Furthermore, the company must navigate ongoing drug pricing pressures and the impact of legislation like the Inflation Reduction Act (IRA), which is set to implement its first Medicare-negotiated drug prices in 2026. While the company's push into specialty services and biopharma provides a buffer, its core distribution margins remain sensitive to pricing dynamics. The upcoming earnings call will be an opportunity for leadership to address how these industry-wide trends are impacting strategy and profitability, and whether the company's growth trajectory remains on its current ambitious path.